Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
Adult Alveolar Soft-part Sarcoma, Adult Angiosarcoma, Adult Epithelioid Sarcoma
About this trial
This is an interventional treatment trial for Adult Alveolar Soft-part Sarcoma
Eligibility Criteria
Inclusion Criteria: Newly diagnosed non-rhabdomyosarcoma soft tissue sarcoma (STS), confirmed by central pathology review via concurrent enrollment on protocol COG-D9902 Metastatic or non metastatic disease Meets 1 of the following criteria: Intermediate (i.e., rarely metastasizing) or malignant STS, including any of the following: Adipocytic tumor, including liposarcoma of any of the following histology subtypes: Dedifferentiated Myxoid Round cell Pleomorphic type Mixed-type Not otherwise specified (NOS) Fibroblastic/myofibroblastic tumors, including any of the following: Solitary fibrous tumor Hemangiopericytoma Low-grade myofibroblastic sarcoma Myxoinflammatory fibroblastic sarcoma Adult fibrosarcoma* Myxofibrosarcoma Low-grade fibromyxoid sarcoma or hyalinizing spindle-cell tumor Sclerosing epithelioid fibrosarcoma So-called fibrohistiocytic tumors, including any of the following: Plexiform fibrohistiocytic tumor Giant cell tumor of soft tissues Pleomorphic malignant fibrous histiocytoma (MFH)/undifferentiated pleomorphic sarcoma Giant cell MFH/undifferentiated pleomorphic sarcoma with giant cells Inflammatory MFH/undifferentiated pleomorphic sarcoma with prominent inflammation Smooth muscle tumor (leiomyosarcoma) Pericytic [perivascular] tumor (malignant glomus tumor or glomangiosarcoma) Vascular tumor, including angiosarcoma Chondro-osseous tumors of any of the following types: Mesenchymal chondrosarcoma Extraskeletal osteosarcoma Tumors of uncertain differentiation, including any of the following: Angiomatoid fibrous histiocytoma Ossifying fibromyxoid tumor Myoepithelioma/parachordoma Synovial sarcoma Epithelioid sarcoma Alveolar soft-part sarcoma Clear cell sarcoma of soft tissue Extraskeletal myxoid chondrosarcoma ("chordoid type") Malignant mesenchymoma Neoplasms with perivascular epithelioid cell differentiation (PEComa) Clear cell myomelanocytic tumor Intimal sarcoma Malignant peripheral nerve sheath tumor Dermatofibrosarcoma protuberans meeting both of the following criteria: Non metastatic disease Tumor must be grossly resected prior to study enrollment Embryonal sarcoma of the liver Unclassified STS that is too undifferentiated to be placed in a specific pathologic category (undifferentiated STS or STS NOS) Gross resection of the primary tumor ≤ 42 days prior to enrollment required except if any of the following circumstances apply: Non metastatic high-grade tumor > 5 cm in maximal diameter and gross or microscopic residual tumor is anticipated after resection Tumor of either high- or- low-grade that cannot be grossly excised without unacceptable morbidity High-grade tumor with metastases Patients with metastatic low-grade tumor whose disease is amenable to gross resection at all sites must undergo gross resection of all sites prior to study entry Patients with a tumor recurrence after a gross total resection are not eligible Tumors arising in bone are not eligible Patients with epithelioid sarcoma, clear cell sarcoma, or clinical or radiologic evidence of regional lymph node enlargement must undergo sentinel lymph node biopsies or lymph node sampling to confirm the status of regional lymph nodes* NOTE: *Except in cases where the study radiologist reviews the imaging and indicates that a biopsy is not needed to confirm that the patient has lymph node involvement. If lymph node biopsies are positive for tumor (or the lymph nodes are classified as positive by the study radiologist), formal lymph node dissection must be done at the time of definitive surgery(prior to study entry for patients assigned to study regimen C) Patients with metastatic disease must undergo a biopsy to confirm the presence of metastatic tumor if all metastases are < 1 cm in maximal diameter (except in cases where the study radiologist reviews the imaging and indicated that a biopsy is not needed to confirm that the patient has metastatic disease) Lansky performance status (PS) 50-100% (for patients ≤ 16 years of age) OR Karnofsky PS 50-100% (for patients > 16 years of age) Life expectancy ≥ 3 months Absolute neutrophil count ≥ 1,000/mm³* Platelet count ≥ 100,000/mm³* Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min (≥ 40 mL/min for infants < 1 year of age)* or serum creatinine based on age and/or gender as follows: 0.4 mg/dL (1 month to < 6 months of age) 0.5 mg/dL (6 months to < 1 year of age) 0.6 mg/dL (1 year to < 2 years of age) 0.8 mg/dL (2 years to < 6 years of age) 1.0 mg/dL (6 years to < 10 years of age) 1.2 mg/dL (10 years to < 13 years of age) 1.5 mg/dL (male) or 1.4 mg/dL (female) (13 years to < 16 years of age) 1.7 mg/dL (male) or 1.4 mg/dL (female) (≥ 16 years of age) Patients with urinary tract obstruction by tumor must meet the renal function criteria listed above AND must have unimpeded urinary flow established via decompression of the obstructed portion of the urinary tract Bilirubin ≤ 1.5 times upper limit of normal (ULN)* Shortening fraction ≥ 27% by echocardiogram* OR ejection fraction ≥ 50% by radionuclide angiogram* Not pregnant or nursing (patients undergoing radiotherapy and/or chemotherapy) No nursing for ≥ 1 month after completion of study treatment in study regimens C or D Fertile patients must use effective contraception during and for ≥ 1 month after completion of study treatment Negative pregnancy test No evidence of dyspnea at rest* No exercise intolerance* Resting pulse oximetry reading > 94% on room air (for patients with respiratory symptoms)* Prior treatment for cancer allowed provided the patient meet the prior therapy requirements No prior anthracycline (e.g., doxorubicin or daunorubicin) or ifosfamide chemotherapy for patients enrolled on arm C or arm D No prior radiotherapy to tumor-involved sites
Sites / Locations
- University of Alabama at Birmingham
- Phoenix Childrens Hospital
- University of Arizona Health Sciences Center
- University of Arkansas for Medical Sciences
- Children's Oncology Group
- Southern California Permanente Medical Group
- City of Hope Medical Center
- Loma Linda University Medical Center
- Miller Children's Hospital
- Children's Hospital Los Angeles
- Cedars-Sinai Medical Center
- David Geffen School of Medicine at UCLA
- Children's Hospital Central California
- Children's Hospital and Research Center at Oakland
- Kaiser Permanente-Oakland
- Childrens Hospital of Orange County
- Lucile Packard Children's Hospital Stanford University
- Rady Children's Hospital - San Diego
- University of California San Francisco Medical Center-Parnassus
- Children's Hospital Colorado
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
- Connecticut Children's Medical Center
- Yale University
- Alfred I duPont Hospital for Children
- Children's National Medical Center
- Broward Health Medical Center
- Lee Memorial Health System
- University of Florida
- Memorial Healthcare System - Joe DiMaggio Children's Hospital
- Nemours Children's Clinic - Jacksonville
- University of Miami Miller School of Medicine-Sylvester Cancer Center
- Miami Children's Hospital
- Baptist Hospital of Miami
- Florida Hospital
- M D Anderson Cancer Center- Orlando
- Nemours Childrens Clinic - Orlando
- Nemours Children's Clinic - Pensacola
- All Children's Hospital
- Saint Joseph Children's Hospital of Tampa
- Saint Mary's Hospital
- Children's Healthcare of Atlanta - Egleston
- Memorial Health University Medical Center
- University of Hawaii
- Tripler Army Medical Center
- Saint Luke's Mountain States Tumor Institute
- University of Illinois
- Childrens Memorial Hospital
- University of Chicago Comprehensive Cancer Center
- Loyola University Medical Center
- Advocate Hope Children's Hospital
- Advocate Lutheran General Hospital
- Saint Jude Midwest Affiliate
- Southern Illinois University
- Riley Hospital for Children
- Saint Vincent Hospital and Health Services
- University of Iowa Hospitals and Clinics
- University of Kentucky
- Kosair Children's Hospital
- Tulane University Health Sciences Center
- Eastern Maine Medical Center
- Maine Children's Cancer Program
- University of Maryland Greenebaum Cancer Center
- Sinai Hospital of Baltimore
- Johns Hopkins University
- Walter Reed National Military Medical Center
- Massachusetts General Hospital Cancer Center
- Dana-Farber Cancer Institute
- University of Massachusetts Medical School
- C S Mott Children's Hospital
- Wayne State University
- Saint John Hospital and Medical Center
- Hurley Medical Center
- Helen DeVos Children's Hospital at Spectrum Health
- Kalamazoo Center for Medical Studies
- Michigan State University - Breslin Cancer Center
- Children's Hospitals and Clinics of Minnesota - Minneapolis
- University of Minnesota Medical Center-Fairview
- Mayo Clinic
- University of Mississippi Medical Center
- University of Missouri-Columbia
- The Childrens Mercy Hospital
- Washington University School of Medicine
- Saint John's Mercy Medical Center
- University of Nebraska Medical Center
- Nevada Cancer Research Foundation CCOP
- Dartmouth Hitchcock Medical Center
- Hackensack University Medical Center
- Saint Peter's University Hospital
- UMDNJ - Robert Wood Johnson University Hospital
- Newark Beth Israel Medical Center
- Saint Joseph's Regional Medical Center
- Overlook Hospital
- University of New Mexico Cancer Center
- Albany Medical Center
- Montefiore Medical Center
- Brooklyn Hospital Center
- Roswell Park Cancer Institute
- The Steven and Alexandra Cohen Children's Medical Center of New York
- New York University Langone Medical Center
- Mount Sinai Medical Center
- Columbia University Medical Center
- University of Rochester
- Stony Brook University Medical Center
- State University of New York Upstate Medical University
- New York Medical College
- Mission Hospitals Inc
- University of North Carolina
- Carolinas Medical Center
- Presbyterian Hospital
- Duke University Medical Center
- Wake Forest University Health Sciences
- Sanford Medical Center-Fargo
- Children's Hospital Medical Center of Akron
- Cincinnati Children's Hospital Medical Center
- Rainbow Babies and Childrens Hospital
- Cleveland Clinic Foundation
- Nationwide Children's Hospital
- The Children's Medical Center of Dayton
- The Toledo Hospital/Toledo Children's Hospital
- Mercy Children's Hospital
- University of Oklahoma Health Sciences Center
- Legacy Emanuel Children's Hospital
- Legacy Emanuel Hospital and Health Center
- Oregon Health and Science University
- Lehigh Valley Hospital - Muhlenberg
- Geisinger Medical Center
- Penn State Hershey Children's Hospital
- Children's Hospital of Philadelphia
- Children's Hospital of Pittsburgh of UPMC
- Rhode Island Hospital
- Palmetto Health Richland
- Greenville Cancer Treatment Center
- Sanford USD Medical Center - Sioux Falls
- T C Thompson Children's Hospital
- East Tennessee Childrens Hospital
- St. Jude Children's Research Hospital
- Vanderbilt-Ingram Cancer Center
- Texas Tech University Health Science Center-Amarillo
- Dell Children's Medical Center of Central Texas
- Driscoll Children's Hospital
- Medical City Dallas Hospital
- University of Texas Southwestern Medical Center
- Brooke Army Medical Center
- Cook Children's Medical Center
- Baylor College of Medicine
- M D Anderson Cancer Center
- Covenant Children's Hospital
- University of Texas Health Science Center at San Antonio
- Methodist Children's Hospital of South Texas
- Scott and White Memorial Hospital
- Primary Children's Medical Center
- University of Vermont
- University of Virginia
- Inova Fairfax Hospital
- Childrens Hospital-King's Daughters
- Virginia Commonwealth University
- Seattle Children's Hospital
- Providence Sacred Heart Medical Center and Children's Hospital
- Mary Bridge Children's Hospital and Health Center
- Madigan Army Medical Center
- West Virginia University Charleston
- Saint Vincent Hospital
- University of Wisconsin Hospital and Clinics
- Marshfield Clinic
- Midwest Children's Cancer Center
- Sydney Children's Hospital
- The Children's Hospital at Westmead
- Royal Brisbane and Women's Hospital
- Women's and Children's Hospital-Adelaide
- Royal Children's Hospital
- Princess Margaret Hospital for Children
- Alberta Children's Hospital
- University of Alberta Hospital
- British Columbia Children's Hospital
- CancerCare Manitoba
- Janeway Child Health Centre
- IWK Health Centre
- Chedoke-McMaster Hospitals
- Cancer Centre of Southeastern Ontario at Kingston General Hospital
- Children's Hospital of Eastern Ontario
- Hospital for Sick Children
- The Montreal Children's Hospital of the MUHC
- Hospital Sainte-Justine
- Centre Hospitalier Universitaire de Quebec
- Saskatoon Cancer Centre
- Starship Children's Hospital
- San Jorge Children's Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Experimental
Experimental
Arm A: No adjuvant treatment
Arm B: Low risk; adjuvant radiotherapy
Arm C: Intermediate & High risk; adjuvant chemoradiotherapy
Arm D: Intermediate & High Risk; Neoadjuvant chemoradiotherapy
Patients with low-grade tumor with either negative or positive microscopic margins or high-grade tumor ≤ 5 cm (in maximum diameter) with negative microscopic margins are assigned to arm A: (observation only).
Patients with high-grade tumor ≤ 5 cm (in maximum diameter) with positive microscopic margins are assigned to arm B: (adjuvant radiotherapy). Beginning between 6-42 days after surgical resection, patients undergo a total of 31 fractions of adjuvant radiotherapy.
High risk [metastatic, resected, incompletely resected, or unresected disease] patients with high-grade, grossly resected primary tumor, with metastases are assigned to receive arm C: (adjuvant chemoradiotherapy). Patients receive ifosfamide IV; doxorubicin hydrochloride IV; beginning in week 4, patients also undergo a total of 31 fractions of radiotherapy.
High risk [metastatic, resected, incompletely resected, or unresected disease] patients with unresected, high-grade metastatic tumor are assigned to receive treatment as in arm D: (neoadjuvant chemoradiotherapy, surgery, and adjuvant chemotherapy with or without radiotherapy): Patients receive ifosfamide IV; doxorubicin hydrochloride IV. Beginning in week 4, patients also undergo a total of 31 fractions of radiotherapy. Patients undergo surgical resection in week 13.